1. Detection and Characterization of VIM-52, a New Variant of VIM-1 from a Klebsiella pneumoniae Clinical Isolate.
- Author
-
de Barsy M, Mercuri PS, Oueslati S, Elisée E, Huang TD, Sacré P, Iorga BI, Naas T, Galleni M, and Bogaerts P
- Subjects
- Ceftazidime pharmacology, Microbial Sensitivity Tests, beta-Lactamases genetics, Anti-Bacterial Agents pharmacology, Klebsiella pneumoniae genetics
- Abstract
Over the last two decades, antimicrobial resistance has become a global health problem. In Gram-negative bacteria, metallo-β-lactamases (MBLs), which inactivate virtually all β-lactams, increasingly contribute to this phenomenon. The aim of this study is to characterize VIM-52, a His224Arg variant of VIM-1, identified in a Klebsiella pneumoniae clinical isolate. VIM-52 conferred lower MICs to cefepime and ceftazidime compared to VIM-1. These results were confirmed by steady-state kinetic measurements, where VIM-52 yielded a lower activity toward ceftazidime and cefepime but not against carbapenems. Residue 224 is part of the L10 loop (residues 221 to 241), which borders the active site. As Arg 224 and Ser 228 both play an important and interrelated role in enzymatic activity, stability, and substrate specificity for the MBLs, targeted mutagenesis at both positions was performed and further confirmed their crucial role for substrate specificity.
- Published
- 2021
- Full Text
- View/download PDF